(Q40650481)

22 September 2017

Design, construction, and in vitro analyses of multivalent antibodies (English)

1 reference

22 September 2017

Design, Construction, and In Vitro Analyses of Multivalent Antibodies (English)

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

30 December 2023

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

30 December 2023

author name string

Kathy Miller

1

1 reference

22 September 2017

Gloria Meng

2

1 reference

22 September 2017

Jun Liu

3

1 reference

22 September 2017

Amy Hurst

4

1 reference

22 September 2017

Vanessa Hsei

5

1 reference

22 September 2017

Wai-Lee Wong

6

1 reference

22 September 2017

Rene Ekert

7

1 reference

22 September 2017

David Lawrence

8

1 reference

22 September 2017

Steven Sherwood

9

1 reference

22 September 2017

Laura DeForge

10

1 reference

22 September 2017

Jacques Gaudreault

11

1 reference

22 September 2017

Gilbert Keller

12

1 reference

22 September 2017

Mark Sliwkowski

13

1 reference

22 September 2017

Avi Ashkenazi

14

1 reference

22 September 2017

Leonard Presta

15

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

22 September 2017

published in

Journal of Immunology

1 reference

22 September 2017

170

1 reference

22 September 2017

9

1 reference

22 September 2017

4854-4861

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

22 September 2017

1

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Use of rituximab, the new FDA-approved antibody.

30 December 2023

2

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

30 December 2023

4

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

30 December 2023

5

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

30 December 2023

6

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Enhancing tumor targeting and apoptosis using noncovalent antibody homodimers

30 December 2023

7

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Dimerization as a regulatory mechanism in signal transduction

30 December 2023

8

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Endocytosis and mitogenic signaling

30 December 2023

9

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds

30 December 2023

11

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Effects of various forms of monoclonal anti-Fc gamma R II (2.4G2) on B lymphocyte responses

30 December 2023

12

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells

30 December 2023

13

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Recombinant chimeric OKT3/IgM antibodies for immune suppression: evaluation in a human CD3 transgenic mouse model

30 December 2023

14

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Design and production of novel tetravalent bispecific antibodies

30 December 2023

16

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

New protein engineering approaches to multivalent and bispecific antibody fragments

30 December 2023

17

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

30 December 2023

18

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region

30 December 2023

20

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Stability engineering of antibody single-chain Fv fragments

30 December 2023

21

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides

30 December 2023

22

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity

30 December 2023

23

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

30 December 2023

24

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Herceptin: from the bench to the clinic

30 December 2023

25

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Death receptors: signaling and modulation

30 December 2023

27

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule

30 December 2023

29

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Rapid and efficient site-specific mutagenesis without phenotypic selection

30 December 2023

30

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

30 December 2023

32

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Kinetic and Concentration Analysis Using BIA Technology

30 December 2023

33

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors

30 December 2023

34

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Analytical ultracentrifugation in the pharmaceutical industry

30 December 2023

35

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

30 December 2023

36

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Safety and antitumor activity of recombinant soluble Apo2 ligand

30 December 2023

37

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

30 December 2023

39

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids

30 December 2023

41

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity

30 December 2023

42

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

30 December 2023

43

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Apoptosis control by death and decoy receptors

30 December 2023

44

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Caspases: preparation and characterization

30 December 2023

45

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

30 December 2023

47

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile

30 December 2023

48

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Engineered humanized dimeric forms of IgG are more effective antibodies

30 December 2023

49

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

30 December 2023

52

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

30 December 2023

53

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Recombinant antibody constructs in cancer therapy

30 December 2023

54

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

An open study of B lymphocyte depletion in systemic lupus erythematosus

30 December 2023

57

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy

30 December 2023

58

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment

30 December 2023

59

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

30 December 2023

60

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

Recombinant immunotoxins in targeted cancer cell therapy

30 December 2023

62

1 reference

https://api.crossref.org/works/10.4049/JIMMUNOL.170.9.4854

30 December 2023

Identifiers

1 reference

22 September 2017

1 reference